Adjuvant chemotherapy for stage I non-seminomatous XXXX .

@entity1 @entity137 @entity5 @entity900 @entity2879 @entity1732
Developments in the treatment of stage I testicular non-seminomatous germ cell @entity5 have aimed primarily at reducing morbidity since the introduction of retroperitoneal lymph node dissection. Surveillance after orchidectomy, i.e. follow-up alone with chemotherapy only for relapsed disease, was found to be logistically and psychologically taxing for @entity1 . Risk factors for relapse were, however, identified from analyses of @entity5 histology of the orchidectomy specimen. Between September 1988 and April 1992, 20 @entity1 with clinical stage I testicular non-seminomatous germ cell @entity5 and a relatively high risk of relapse were entered into a prospective study of adjuvant chemotherapy. The chemotherapy regimen consisted of 2 cycles of @entity900 , @entity2879 and @entity1732 . Each cycle of chemotherapy lasted 3 days. There have been no relapses at a median follow-up of 31 months (range 12-53 months). Acute and late @entity137 have been modest. We have found adjuvant chemotherapy to be effective after orchidectomy in @entity1 with stage I disease with adverse prognostic factors for relapse.
